Authors

Michael Keating, MB, BS, University of Texas MD Anderson Cancer Center

Latest:

Translating Combination Radiotherapy/Immunotherapy From Dogs to Humans With Advanced Melanoma or Sarcoma

Arta Monjazeb, MD, and Michael Kent, DVM, from the UC Davis Comprehensive Cancer Center, describe an early phase trial exploring the potential of translating successful treatment from dogs to humans with advanced melanoma or sarcoma.

Michael Kolodziej, MD

Latest:

The Oncology Care Model: Roadmap or Distraction for Commercial Payers?

It's clear that Medicare needs a proactive cancer strategy, hence the launch of the Oncology Care Model.

Michael Kolodziej, MD, Aetna

Michael Krauthammer, MD, PhD

Latest:

Dr. Michael Krauthammer on NF1 Mutations in Melanoma

Michael Krauthammer, MD, PhD, Associate Professor of Pathology, Yale School of Medicine, discusses the role of NF1 mutation in melanoma.

Michael L. Blute, MD

Latest:

Dr. Blute on Kidney-Sparing Surgery Vs Radical Nephrectomy in RCC

Michael L. Blute, MD, chair of Department of Urology, Massachusetts General Hospital, discusses the differences between kidney-sparing surgery and radical nephrectomy for patients with renal cell carcinoma (RCC).

Michael L. Grossbard, MD

Latest:

Fellows on Film: What Makes a Good Mentor for an Oncology Fellow?

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss the qualities that make someone a great mentor for an oncology fellow.

Michael L. Krychman, MD

Latest:

Dr. Krychman on Treating Cancer-Related Sexual Issues

Michael L. Krychman, MD, Executive Director of the Southern California Center for Sexual Health and Survivorship Medicine, discusses managing and treating sexual health concerns in cancer patients and survivors.

Michael L. Wang, MD University of Texas MD Anderson Cancer Center

Latest:

Dr. Shah and Dr. Wang on the Need for Academic and Community Collaboration With CAR T-Cell Therapy

Bijal Shah, MD, MS, and Michael Wang, MD, discuss the need for collaboration between academic and community practices for patients who receive CAR T-cell therapy.

Michael Lim, MD

Latest:

Dr. Michael Lim on Toxicities of Checkpoint Inhibitors

Michael Lim, MD, Director of Brain Tumor Immunotherapy, Associate Professor of Neurosurgery, Johns Hopkins Medicine, discusses toxicities associated with checkpoint inhibitors for the treatment of glioblastoma.

Michael Link, MD

Latest:

Dr. Link on Evolution of Treatment in Pediatric Cancer

Michael Link, MD, professor of pediatrics, Stanford Cancer Institute, 2018 Giant of Cancer Care in Pediatrics, discusses the evolution of treatment in pediatric cancer.

Michael Manns, MD

Latest:

Dr. Manns on Risk Factors for Hepatitis C-Related Hepatocellular Carcinoma

Michael Manns, MD, the Director of the Department of Gastroenterology, Hepatology and Endocrinology at the Medical School of Hannover in Germany, explains risk factors for hepatitis C-related hepatocellular carcinoma.

Michael Marlan Mohundro, PharmD

Latest:

On the Horizon for Multiple Myeloma: Update on Novel Agents, Bone Therapies

A new generation of proteasome inhibitors, immunomodulatory agents, and deacetylase inhibitors are currently being investigated in clinical trials to treat patients with relapsed or refractory multiple myeloma.

Michael Marlon Mohundro, PharmD

Latest:

Clinical and Economic Considerations for the Use of Erythropoiesis-Stimulating Agents

Erythropoiesis-stimulating agents (ESAs) are genetically engineered forms of erythropoietin that stimulate erythropoiesis through direct or indirect action on the erythropoietin receptor producing an increase

Michael Mauro, MD

Latest:

Dr. Mauro on the Risks of Disease Progression in Myelofibrosis

Michael J. Mauro, MD, discusses the risks of disease progression in myelofibrosis.

Michael Mauro, MD, Memorial Sloan Kettering Cancer Center

Michael Morse, MD, Duke Cancer Institute

Michael P. Link, MD

Latest:

ASCO President Recaps Top Stories From Meeting

Dr. Michael P. Link, ASCO President, from Stanford University School of Medicine, on the top stories from the 2012 ASCO Annual Meeting.

Michael Palese, MD

Latest:

Dr. Palese on Emerging Technologies in Benign Prostatic Hyperplasia

Michael A. Palese, MD, discusses emerging technologies in benign prostatic hyperplasia.

Michael Pishvaian, MD, PhD

Latest:

Dr. Pishvaian Discusses Atezolizumab Plus Bevacizumab in HCC

Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in patients with hepatocellular carcinoma.